Indications for SIVEXTRO:
Susceptible acute bacterial skin and skin structure infections (ABSSSI).
Adults and Children:
<12yrs: not established. ≥12yrs: 200mg once daily for 6 days.
Not adequately evaluated in patients with neutropenia (ANC <1000 cells/mm3); consider alternate therapies. Risk of C. difficile-associated diarrhea; discontinue if suspected or confirmed. Pregnancy. Nursing mothers.
Tabs: May potentiate oral BCRP substrates; consider interrupting co-administered substrates esp. those with narrow therapeutic index (eg, methotrexate, topotecan); monitor if coadministration (including rosuvastatin) is necessary.
Nausea, headache, diarrhea, infusion- or inj site reactions, vomiting, dizziness. In children: phlebitis, increased hepatic transaminases.
Tabs—6 (blister pack), 30; single-dose vials—10